Kymera Investor Presentation Deck

● ● ● QTc Prolongation Spontaneously Resolves to Baseline by Day 28 AQTCF in Part C is in the range observed in MAD3 (100 mg QD) up to Day 14 Declines to baseline with continued dosing and sustained plasma exposure through Day 28 Profile is maintained through day 42 upon cessation of dosing after Day 28 No QTc-related AEs observed AQTcF QTcF Mean MAD3 Part C MAD3 Part C n=9 for MAD3 and n=20 for Part C, except day 14 (n=19) KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. Baseline 395 Change from Baseline QTcF (ms) Mean (± 90% CI) 403 20 15 10 5 O -5 Day 7 17 15 411 419 Day 14 13 12 408 416 Day 21 5.9 -- 410 MAD3 PART C Day 28 1.6 405 PAGE 32

View entire presentation